Bishal Gyawali, Medical Oncologist, Professor at Queen’s University, shared a post on LinkedIn:
“Our new paper in JNCI discusses why Destiny Breast 11 and SERENA-6 should not lead to regulatory approval but IMvigor 011 should. Dynamic 3 should give us a pause on our enthusiasm re ctDNA.
Read for a primer on predictive versus prognostic biomarkers in oncology.”
Title: Critical appraisal: prognostic versus predictive surrogate markers in oncology
Authors: Aliyah Pabani, Bishal Gyawali
Other articles featuring Bishal Gyawali on OncoDaily.
